Nanostics Inc. is at the forefront of precision health, focusing on the development of innovative tools to enhance healthcare decision-making. Their flagship product, ClarityDX Prostate, leverages clinical features and blood-based biomarkers to assess a patient's risk of aggressive prostate cancer. This technology aims to empower both patients and healthcare providers by providing more accurate predictions, thereby reducing the need for invasive prostate biopsies, which can be uncomfortable and carry associated risks. The company emphasizes the importance of informed healthcare decisions, particularly in the context of prostate cancer screening.

The ClarityDX platform utilizes advanced technology that integrates machine learning with data derived from proprietary and non-proprietary biomarkers found in biofluids such as blood and urine. Central to this technology are extracellular vesicles (EVs), which are released from cells and present in various biological fluids. Nanostics employs microflow cytometry to analyze these EVs, quantifying their size, concentration, and marker abundance rapidly. By combining this biomarker data with clinical information, the ClarityDX platform aims to deliver precise and timely results, ultimately transforming the landscape of disease screening and management.

Canada

Nanostics develops and commercializes novel, non-invasive diagnostic tests for cancer. Our core technology is an advanced liquid biopsy platform that can accurately diagnose cancer from a single drop of blood. Our lead product, ClarityDx Prostate, is the most accurate diagnostic test to diagnose aggressive prostate cancer. Go to https://www.nanosticsdx.com/clarity-dx-prostate/ to order ClarityDX Prostate today.

Nanostics Inc.

Company Details